LUMENS-1 Canada Early Feasibility Study Clinical Investigation Plan
A legfontosabb adatok
- Ki végzi
- LuSeed Vascular LTD.
- Hol
- Kanada1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 10 fő, tervezett
- Kezdés
- 2025. dec.
- Várható befejezés
- 2028. máj.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- LuSeed Aneurysm Embolization System
- A regiszteradat frissítve
- 2025. december 9.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with an unruptured brain aneurysm at a vessel branching point. They must be able to have a planned treatment from inside the blood vessel with the LuSeed device.
- Életkor
- 18-80 years
- Nem
- All sexes
- A betegség stádiuma
- Unruptured, sac-shaped, wide-neck brain aneurysm at a vessel branching point, front or back circulation. Treatment is needed by AHA / ASA Guidelines. Width 2.5-5.5 mm, neck 2.0-5.0 mm, height at least 4.0 mm (short device) or 5.0 mm (long device).
- Korábbi kezelés
- The target aneurysm cannot already hold other devices or implants, such as coils.
A részvétel fő kizáró okai
- Ruptured brain aneurysm
- Narrowing of the main vessel of the aneurysm over 50%
- Known allergy to platinum, nickel, titanium or contrast agents
- Stroke, TIA, brain embolism or heart attack in the past 6 months
- Pregnant, breastfeeding or planning pregnancy within 12 months
A regiszter feltételei, szó szerint
Mind a 28 feltétel megnézéseKevesebb
Ki vehet részt
- Patients indicated for treatment of unruptured intracranial aneurysms (IA) according to AHA / ASA Guidelines
- Age 18-80 years at screening
- Patients who are suitable for non-emergency endovascular embolization of saccular IAs
- The IA must have had the following characteristics:; IA located in bifurcation in the anterior or posterior circulation; IA dimensions appropriate for treatment with LuSeed- Vascular Embolization Device per implant size selection guidelines as outlined in the Instructions for; Use (IFU) and as follows:; IA Width: 2.5-5.5[mm]; IA Neck: 2.0-5.0[mm]; IA Height: min 4.0 [mm]- device short configuration, min 5.0 [mm]-device long configuration • The AI must meet the definition of a "wide-neck" aneurysm
- Patient is willing and able to participate in the study for the duration of the study follow-up and can comply with study requirements
- Patient able to give their informed consent can be included in this study
Ki nem vehet részt
- Target Intracranial aneurysm contains other devices/implants (e.g., coils)
- Absolute contraindication to anticoagulation or antiplatelet therapy
- Anticoagulation medications such as warfarin that cannot be discontinued
- Any other medical issue within the brain that would preclude device implantation (such as brain surgery, radiation in the target area of intervention from an external beam source, acute traumatic craniocerebral injury, etc.)
- Current participation in another study with investigational devices or drugs that would confound the effect of the study outcomes
- Known allergy to platinum, nickel, or titanium
- Known allergy to contrast agents
- Acute or chronic renal failure (stage III or IV by VARC-3 criteria)
- Cerebral embolism, stroke, or TIA in past 6 months
- Myocardial infarction in the past 6 months
- Patient had any circulatory, neurovascular, cardiovascular, or neurologic conditions that resulted in unstable neurological symptoms at screening
- Patient had physical, neurologic or psychiatric conditions which precluded his/her ability to comply with all aspects of the screening, evaluation, treatment, and the postprocedure follow-up schedule
- Other medical conditions that cause an inability to comply with study requirements and/or that could increase the risk of neurovascular procedures (e.g., extreme frailty, liver failure, cancer, heart failure, chronic obstructive pulmonary disease, immunosuppression, neural disease, and hematologic disorders etc.)
- Ruptured intracranial aneurysm
- Patient anatomy or physiology considered unsuitable for endovascular treatment as determined by imaging Core Lab
- Contraindication for arterial access
- Intracranial aneurysm neck diameter less than 2mm or greater than 5 mm
- Intracranial aneurysm sac diameter less than 2.5mm or greater than 5.5mm
- Intracranial aneurysm minimum height less than 4.0 mm
- Stenosis of the target IA's parent vessel >50%
- Pregnant, breastfeeding or planning pregnancy within next 12 months
- Patient had a life expectancy of less than 12 months
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 80 év között vagy?
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The primary objective of this clinical investigation is to evaluate the early safety and feasibility of the LuSeed Aneurysm Embolization System for treating unruptured intracranial aneurysms (IA). This is a single-arm, open-label, single-center, interventional study, screening patients approved for treatment of unruptured IAs based on national or international guidelines. Up to 10 eligible subjects meeting inclusion and exclusion criteria and providing consent will be enrolled in a Canadian site.
A vizsgálat csoportja
- LuSeed Aneurysm Embolization SystemA vizsgált kezelés
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Single-arm, Open Label, Single-center Early Feasibility Study of the LuSeed Aneurysm Embolization System in Individuals With Unruptured Intracranial Aneurysms.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT07259018: ki vehet részt
- A regiszteradat frissítve
- 2025. december 9.